TB-006 is under clinical development by TrueBinding and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 49% ...
Dr. Dongxu Sun is the founder and CEO of Truebinding Inc., where he is leading a team of multi-discipline scientists to develop monoclonal antibody drug candidates targeting novel pathogenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results